Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences, Inc.    GILD

GILEAD SCIENCES, INC.

(GILD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Gilead Sciences : Immunomedics Shares More Than Double After Gilead Deal

share with twitter share with LinkedIn share with facebook
09/14/2020 | 09:12am EDT

By Michael Dabaie

 

Immunomedics Inc. shares more than doubled premarket Monday, up 106% to $87.17.

On Sunday, Gilead Sciences Inc. said it would acquire Immunomedics for $88 a share in cash.

The deal, which values Immunomedics at about $21 billion, was unanimously approved by both the Gilead and Immunomedics boards and is anticipated to close during the fourth quarter of 2020, Gilead said. Gilead shares were down 1% to $64.21 premarket.

The deal will provide Gilead with Trodelvy, which was granted accelerated approval by the U.S. Food and Drug Administration for the treatment of adult patients with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease. Immunomedics plans to submit a supplemental biologics license application to support full approval of Trodelvy in the United States in the fourth quarter of 2020. Immunomedics is also on track to file for regulatory approval in Europe in the first half of 2021.

Beyond mTNBC, Trodelvy is also being studied in an ongoing Phase 3 trial in third line HR+/HER2- breast cancer and a registrational Phase 2 study in bladder cancer.

"This acquisition represents significant progress in Gilead's work to build a strong and diverse oncology portfolio. Trodelvy is an approved, transformational medicine for a form of cancer that is particularly challenging to treat. We will now continue to explore its potential to treat many other types of cancer, both as a monotherapy and in combination with other treatments," Gilead Chief Executive Daniel O'Day said.

 

Write to Michael Dabaie at michael.dabaie@wsj.com

 


Stocks mentioned in the article
ChangeLast1st jan.
GILEAD SCIENCES, INC. -3.18% 58.72 Delayed Quote.-10.59%
IMMUNOMEDICS, INC. 0.05% 87.86 End-of-day quote.315.22%
share with twitter share with LinkedIn share with facebook
All news about GILEAD SCIENCES, INC.
11:16aGLOBAL MARKETS LIVE : Microsoft, Deutsche Bank, Sony…
10/26ELI LILLY AND : NIH Halts Study Exploring Treating Covid-19 With Lilly Antibody,..
DJ
10/26ELI LILLY AND : NIH Halts Study Exploring Treating Covid-19 With Lilly Antibody,..
DJ
10/26GILEAD SCIENCES : Completes Acquisition of Immunomedics, Inc.
AQ
10/26LIGAND PHARMACEUTICALS INCORPORATED : Captisol Technology Plays Key Role in the ..
AQ
10/24To Find a Coronavirus Vaccine, GlaxoSmithKline Is Bonding With Its Biggest Co..
DJ
10/24GILEAD SCIENCES : Mexico will not follow FDA in approving Gilead's COVID-19 drug
RE
10/23Stocks mixed; COVID-19 vaccine trials to restart
RE
10/23GILEAD SCIENCES INC : Completion of Acquisition or Disposition of Assets, Other ..
AQ
10/23S&P, Nasdaq close higher as stimulus talks in spotlight
RE
More news
Financials (USD)
Sales 2020 24 037 M - -
Net income 2020 2 282 M - -
Net Debt 2020 14 558 M - -
P/E ratio 2020 35,8x
Yield 2020 4,50%
Capitalization 73 619 M 73 619 M -
EV / Sales 2020 3,67x
EV / Sales 2021 3,53x
Nbr of Employees 11 800
Free-Float 99,6%
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 77,29 $
Last Close Price 60,01 $
Spread / Highest target 75,0%
Spread / Average Target 28,8%
Spread / Lowest Target -5,02%
EPS Revisions
Managers
NameTitle
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
William A. Lee Executive Vice President-Research
Merdad V. Parsey Chief Medical Officer
George Pratt Shultz Director-Emeritus
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES, INC.-10.59%75 236
REGENERON PHARMACEUTICALS50.42%61 299
VERTEX PHARMACEUTICALS-3.97%55 269
WUXI APPTEC CO., LTD.64.97%39 253
BEIGENE, LTD.81.31%27 327
GENMAB A/S48.84%22 921